Search Results for: International Stem Cell Corporation to
Articles
Immunocore Identifies Second Novel ImmTAC in GSK Collaboration May 15, 2017
Immunocore Limited recently announced it has identified a lead compound in its second discovery program with GSK. This novel ImmTAC...Geron Announces Initiation of Janssen Phase II/III Clinical Trial January 18, 2016
Geron Corporation recently announced the dosing of the first patient in a Phase II/III clinical trial to evaluate imetelstat in...ADVANCED DELIVERY DEVICES - Implantable Drug-Eluting Devices: A Novel Approach to Patient Care October 6, 2015
Samuel D. Trohman, MBA, Joey L. Glassco, Elena Draganoiu, PhD, and Carey Boyum present developmental and commercial examples of non-biodegradable drug-eluting devices, along with the versatile properties of thermoplastic polyurethanes for the development of effective drug delivery systems.
EXECUTIVE INTERVIEW - Terumo: Innovating at the Speed of Life for Cutting-Edge Solutions in Medical Devices & Services August 31, 2015
Mr. Juichi “Jim” Takeuchi, Terumo Corporation’s Executive Officer and President of Global Pharmaceutical Solutions, discusses his company’s innovative approach to parenteral drug delivery using integrated science and technology.
FUJIFILM Completes Acquisition of Biotherapeutics Company December 18, 2014
FUJIFILM Diosynth Biotechnologies U.S.A. Inc. (FDBU), a FUJIFILM Corporation subsidiary, recently announced the completion of its acquisition of Kalon Biotherapeutics LLC,...Tekmira Presents Recent Advances in mRNA Delivery February 28, 2014
Tekmira Pharmaceuticals Corporation recently announced that recent advances in the enablement of messenger RNA (mRNA) using Tekmira's lipid nanoparticle (LNP)...SPRAY-DRIED DISPERSIONS - Efficient Scale-Up Strategy for Spray-Dried Amorphous Dispersions October 16, 2013
Devon DuBose, Dana Settell, and John Baumann focus on the methodologies for efficient scale-up of the spray-drying process while maintaining the critical-to-quality attributes of the SDD.
THERAPEUTIC FOCUS - New Therapeutics for Aggressive Brain Cancers October 3, 2013
Jeffrey Bacha, MBA, says glioblastoma is one of the most common and fatal brain cancers, and new therapies to treat this disease are urgently needed. New approaches, such as vaccines and immunotherapies, have promising results, and to be most effective, will need to be used in combination with a chemotherapeutic.
2/27/2012 February 25, 2013
BASF & Bend Research Sign Bioavailability Agreement BASF SE and Bend Research Inc. have signed an agreement to jointly evaluate...12/5/2012 November 29, 2012
Curis Announces Several Major Announcements Curis, Inc. recently announced it has licensed from Genentech, a member of the Roche Group,...11/28/2012 November 26, 2012
CoreRx & ViroPro Announce Agreement CoreRx, Inc. and Viropro, Inc. recently announced the two companies have entered into a Reciprocal...9/19/2012 September 16, 2012
PharmaTelevision Spotlights Aptalis' Year in Review FDA approvals, revenue gain, and organic business growth are just a few of the...9/5/2012 September 3, 2012
Genmab Signs Potential Billion Dollar Agreement Genmab recently announced a global license and development agreement for daratumumab (HuMax-CD38), a human...8/22/2012 August 20, 2012
United Drug Acquires Leading Clinical Trials Materials Business United Drug plc recently announced it has reached an agreement to acquire...8/15/2012 August 12, 2012
Quintiles Acquires Company to Advance Personalized Medicine Quintiles recently announced the acquisition of Expression Analysis, Inc. (EA), a premier provider...7/25/2012 July 19, 2012
Agile Therapeutics Raises $40 Million Agile Therapeutics recently announced it has closed a $40-million Series C financing. The round was...5/16/2012 May 14, 2012
Mucosis Announces Positive Data for Mimopath Platform Mucosis B.V. recently announced Phase I clinical data providing proof-of-concept that Mimopath-based mucosal...3/20/2012 March 15, 2012
Connell Brothers Signs Agreement With World's Top Chemical Company Connell Brothers Australasia recently announced it was appointed by BASF Australia,...3/6/2012 February 29, 2012
Avanir & Concert Announce Exclusive License Agreement Avanir Pharmaceuticals, Inc. and Concert Pharmaceuticals, Inc. recently announced they have entered into...2/7/2012 February 5, 2012
Foster Analytical Services Speed Time to Market for Drug Delivery Formulations Foster Delivery Science, a business unit for Foster Corporation,...
